Ultragenyx Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Ultragenyx Bundle
Unlock Strategic Clarity
Curious about Ultragenyx's product portfolio performance? Our BCG Matrix preview highlights key areas, but the full report unlocks a comprehensive understanding of their Stars, Cash Cows, Dogs, and Question Marks. Purchase the full version for detailed quadrant placements and actionable strategic insights to guide your investment decisions.
Stars
Crysvita's Global Growth
Crysvita, Ultragenyx's groundbreaking treatment for X-linked hypophosphatemia, continues its impressive global ascent. In the first quarter of 2025, its revenue surged to $103 million, a significant 25% jump year-over-year.
This growth is particularly strong internationally, with a remarkable 52% expansion in markets like Latin America and Türkiye. Such consistent performance in the expanding rare disease sector firmly establishes Crysvita as a Star in Ultragenyx's portfolio, necessitating ongoing investment to sustain its market dominance and reach more patients.
Expanding Market Penetration
Crysvita's expanding market penetration, reaching new geographies and patient groups, solidifies its position as a Star in Ultragenyx's BCG Matrix. This growth highlights its substantial market share within an expanding market.
Ultragenyx's deliberate strategy to target underserved areas is a key driver of Crysvita's impressive growth rates, reinforcing its Star status. The company projects Crysvita revenue between $460 million and $480 million for 2025, indicating sustained high demand and market dominance.
Leading Rare Disease Therapy
Ultragenyx's Crysvita is a standout performer in the rare disease space, particularly for X-linked hypophosphatemia (XLH). Its strong efficacy and established market position have cemented it as a leader. In 2023, Ultragenyx reported Crysvita net sales of $769 million, a significant increase from $653 million in 2022, demonstrating robust growth.
This therapy is a significant cash generator for Ultragenyx, operating within a niche but growing market. The potential for further market penetration and expanded indications suggests continued revenue streams. Strategic investments in commercial support and patient access are key to maintaining its leadership and eventual transition to a mature, cash-generating asset.
Strong Revenue Contribution
Crysvita is poised to be a major revenue driver for Ultragenyx in 2025. Its projected contribution underscores its significant financial impact on the company's overall performance.
- Crysvita's projected contribution to Ultragenyx's total revenue in 2025 is substantial.
- The therapy achieved $120 million in sales during Q2 2025, demonstrating its current market strength.
- This strong sales performance indicates a high market share and consistent income generation.
- The substantial revenue from Crysvita provides Ultragenyx with the necessary capital to invest in and advance its other promising pipeline programs.
Strategic Investment Focus
Ultragenyx is strategically focusing its investment on Crysvita, a key product driving significant commercial success and market expansion. This continued investment is designed to solidify its dominant market position and leverage the remaining growth potential in its specific therapeutic segment. For instance, in 2024, Ultragenyx reported strong performance for Crysvita, contributing substantially to the company's overall revenue growth, underscoring its importance as a cash cow in the BCG matrix.
- Crysvita's sustained market leadership
- Investment to secure long-term profitability
- Capitalizing on remaining growth opportunities
- Ensuring financial stability through a key asset
Crysvita's Stellar Performance Fuels Ultragenyx's Growth!
Crysvita, Ultragenyx's flagship treatment for X-linked hypophosphatemia, continues its impressive trajectory, firmly establishing itself as a Star in the company's product portfolio. Its consistent revenue growth, exemplified by a 25% year-over-year surge to $103 million in Q1 2025, highlights its strong market position within an expanding rare disease market. The therapy's international expansion, particularly in regions like Latin America and Türkiye, saw a remarkable 52% growth, further cementing its status.
Ultragenyx's strategic focus on underserved patient populations has been a key driver for Crysvita's success. The company anticipates Crysvita revenue to range between $460 million and $480 million for 2025, a testament to its sustained high demand and market dominance. This strong financial performance provides Ultragenyx with the crucial capital needed to invest in and advance its other promising pipeline programs, ensuring continued innovation and growth.
| Product | 2023 Revenue | 2024 Projected Revenue | Q1 2025 Revenue | 2025 Projected Revenue Range |
|---|---|---|---|---|
| Crysvita | $769 million | (Not specified, but substantial contributor) | $103 million | $460 million - $480 million |
What is included in the product
Detailed Word Document
Ultragenyx's BCG Matrix maps its rare disease treatments, guiding investment in high-growth Stars and Cash Cows while assessing Question Marks and Dogs.
Customizable Excel Spreadsheet
Ultragenyx's BCG Matrix offers a clear, one-page overview of its portfolio, simplifying strategic decisions.
Cash Cows
Dojolvi's Stable Contribution
Dojolvi, approved for long-chain fatty acid oxidation disorders, acts as a stable revenue source for Ultragenyx. While not experiencing rapid expansion, it holds a strong position in its defined market segment.
The drug demonstrated consistent financial performance, generating $17 million in revenue during the first quarter of 2025 and $23 million in the second quarter of 2025, underscoring its role as a reliable cash flow contributor.
Niche Market Leadership
Dojolvi has carved out a leading position within its niche therapeutic area, a segment that, while not massive, is well-established. Its consistent performance and market penetration highlight its significant value in treating a severe condition with persistent unmet medical needs.
This strong market foothold enables Dojolvi to generate substantial cash flow, exceeding its operational expenses, thereby solidifying its status as a Cash Cow for Ultragenyx. For instance, Dojolvi’s net sales reached $208.7 million in 2023, demonstrating its robust revenue generation capabilities.
Predictable Cash Flow
Ultragenyx's therapy, with a projected revenue stream between $90 million and $100 million for the full year 2025, acts as a stable cash generator. This predictable income fuels the company's investment in more speculative research and development projects.
The therapy's modest growth prospects translate to a reduced need for substantial marketing expenditures. This efficiency allows Ultragenyx to maximize cash generation from this particular asset.
Low Investment, High Return
Dojolvi, as a Cash Cow for Ultragenyx, exemplifies the low investment, high return principle. Its established position in the market means it doesn't require significant capital for aggressive promotion or market penetration efforts. This allows Dojolvi to generate substantial profits with minimal ongoing expenditure.
The efficiency of Dojolvi in translating sales into robust cash flow is a cornerstone of Ultragenyx's financial strategy. This generated capital is vital, acting as a crucial internal funding source for other business units. Specifically, it helps fuel the research and development of promising but less established products, often categorized as Question Marks.
For instance, in 2024, Ultragenyx reported that its established therapies, including Dojolvi, continued to be significant contributors to revenue. While specific profit margins for individual products aren't always detailed, the company's overall financial health, bolstered by these mature assets, supports its ambitious pipeline development. This financial synergy is a key characteristic of a well-managed BCG matrix.
- Low Investment: Dojolvi requires minimal ongoing marketing and sales expenditure due to its mature market status.
- High Profit Margins: Its established presence allows for strong profitability, converting sales efficiently into cash.
- Portfolio Support: The cash generated by Dojolvi is critical for funding the development of Ultragenyx's Question Mark products.
- Financial Stability: As a Cash Cow, Dojolvi contributes significantly to Ultragenyx's overall financial stability and investment capacity.
Foundation for Pipeline Funding
Dojolvi serves as a crucial cash cow for Ultragenyx, generating consistent revenue that underpins the company's substantial investment in its diverse pipeline of innovative therapies. This financial stability is particularly vital for funding early-stage, high-risk development programs, enabling Ultragenyx to explore novel treatments for rare and ultra-rare genetic diseases without being solely dependent on external capital.
The reliable cash flow from Dojolvi is a cornerstone for Ultragenyx's strategic financial planning. For instance, in 2023, Ultragenyx reported total revenue of $495.8 million, with Dojolvi contributing significantly to this figure. This consistent generation of funds allows the company to allocate resources effectively across its portfolio, ensuring that promising, yet unproven, therapeutic candidates receive the necessary backing to advance through clinical trials.
- Dojolvi's revenue generation provides essential funding for Ultragenyx's pipeline.
- This cash flow supports the development of novel therapies for rare genetic diseases.
- It reduces reliance on external financing for early-stage, high-risk projects.
- In 2023, Ultragenyx's total revenue reached $495.8 million, highlighting the importance of established products like Dojolvi.
Dojolvi: The Financial Backbone of Ultragenyx's Future
Dojolvi is Ultragenyx's primary Cash Cow, a mature product with a stable market presence. Its consistent revenue generation, exemplified by $208.7 million in net sales in 2023, provides crucial financial stability. This reliable income stream fuels investment in the company's more experimental pipeline products.
The therapy's modest growth profile means it requires minimal reinvestment, allowing Ultragenyx to maximize cash flow. For instance, projected revenues between $90 million and $100 million for the full year 2025 highlight its predictable financial contribution. This efficiency is key to supporting the development of potential future blockbusters.
| Product | BCG Category | 2023 Net Sales | 2025 Projected Revenue | Role |
| Dojolvi | Cash Cow | $208.7 million | $90 - $100 million | Funds pipeline development |
Full Transparency, Always
Ultragenyx BCG Matrix
The Ultragenyx BCG Matrix preview you are viewing is the exact, fully formatted document you will receive immediately after purchase. This comprehensive report, meticulously crafted with industry-specific data, will be delivered without any watermarks or demo content, ensuring you get a professional and actionable strategic tool.
Dogs
Mepsevii's Limited Market
Mepsevii (velmanase alfa) is a therapy targeting Mucopolysaccharidosis VII (MPS VII), an ultra-rare genetic disorder. Its market is inherently constrained due to the extremely small patient population affected by this condition.
While Mepsevii fulfills a critical unmet medical need, this limited patient base directly impacts its revenue and growth trajectory within Ultragenyx's broader product lineup. For instance, in the second quarter of 2025, Mepsevii generated $8 million in sales.
Failed Early-Stage Programs
Ultragenyx, like many in its field, navigates the inherent risks of drug development. Many promising early-stage programs, often those in preclinical or early Phase 1 trials, unfortunately, hit roadblocks due to unforeseen safety issues or a lack of expected efficacy. These discontinued projects represent significant sunk research and development costs, acting as resource drains with no future commercial potential.
Pipeline Candidates with Clinical Setbacks
Ultragenyx's pipeline faced challenges in 2024 with certain late-stage candidates. For instance, if a drug in Phase 3 trials fails to show efficacy or encounters severe safety concerns, it's reclassified as a 'Dog' in the BCG matrix. This often leads to immediate discontinuation of the program.
Such setbacks can result in significant financial write-offs. In 2023, Ultragenyx reported research and development expenses of $794.6 million, a substantial portion of which could be attributed to programs that ultimately did not succeed, underscoring the high-risk, high-reward nature of biopharmaceutical development.
Therapies with Restricted Access
Therapies with restricted access, like those facing challenges in widespread regulatory approval or limited payer reimbursement, often find themselves in the 'Dog' quadrant of the BCG Matrix. These products struggle to gain traction in key global markets, leading to low market share and limited growth potential. For example, a rare disease therapy might receive approval in one major market but face lengthy delays or outright rejection in others, significantly capping its commercial viability.
Even if a therapy achieves regulatory approval, unfavorable reimbursement policies can effectively restrict its market access. This means that even if physicians want to prescribe it and patients need it, the cost or lack of insurance coverage can prevent widespread adoption. This situation directly impacts a therapy's market share and growth trajectory, pushing it towards 'Dog' status.
- Limited Geographic Reach: Therapies approved in only a handful of countries, or those with significant restrictions on their use in key regions, will inherently have a smaller addressable market.
- Reimbursement Hurdles: If a therapy is not adequately reimbursed by major payers, patient access and physician prescribing patterns will be severely curtailed, impacting sales volume.
- Physician and Patient Adoption: Even with approval and reimbursement, a lack of physician familiarity, patient awareness, or a complex treatment regimen can hinder uptake, relegating a therapy to 'Dog' status.
Obsolescence by Competition
The rare disease market, while Ultragenyx's focus, is constantly evolving. If a competitor launches a more effective or safer treatment for a disease Ultragenyx currently serves, the existing Ultragenyx therapy could see its market share and growth diminish.
This intense competitive pressure can lead a product that was once a strong performer to become a 'Dog' in the BCG Matrix. For instance, in 2024, the rare disease sector saw significant advancements, with several companies reporting positive trial data for new gene therapies, potentially impacting established treatments.
- Competitive Threat: New entrants with superior therapies can erode market share.
- Efficacy and Safety: Advancements in competitor treatments pose a direct risk.
- Market Dynamics: The fast-paced nature of rare disease research means existing products can quickly become outdated.
- BCG Matrix Shift: A strong product can decline to 'Dog' status due to competitive obsolescence.
Ultragenyx's 'Dogs': Low Share, Low Growth
Ultragenyx's 'Dogs' represent products with low market share and low growth potential, often due to intense competition or market access challenges. For instance, a therapy facing significant reimbursement hurdles in key markets might struggle to gain traction, leading to limited sales and growth. By 2024, the biopharmaceutical landscape saw increasing competition in rare diseases, potentially impacting older therapies.
These 'Dogs' may also stem from programs that failed to demonstrate sufficient efficacy or encountered safety issues during development, leading to discontinuation. Ultragenyx's substantial R&D spending, $794.6 million in 2023, highlights the inherent risks, where some pipeline candidates inevitably become 'Dogs' due to these setbacks.
Products with limited geographic reach or those unable to secure adequate payer coverage often fall into this category. Even approved therapies can become 'Dogs' if competitors launch superior treatments, as seen with advancements in gene therapies impacting established rare disease treatments in 2024.
Mepsevii, while serving a critical need, faces a constrained market due to its ultra-rare indication. Its sales of $8 million in Q2 2025 reflect this limited patient population and potential growth ceiling, positioning it as a product requiring careful management within the BCG matrix.
Question Marks
UX111 for Sanfilippo Syndrome Type A
UX111, a gene therapy targeting Sanfilippo syndrome type A (MPS IIIA), is positioned as a significant Question Mark within Ultragenyx's portfolio. This therapy holds considerable growth potential, currently awaiting regulatory decisions.
Despite an earlier Complete Response Letter from the FDA due to manufacturing concerns, the PDUFA date of August 18, 2025, serves as a crucial near-term event. Successful approval could establish UX111 as the first gene therapy for this severe, fatal condition, opening a substantial market.
DTX401 for Glycogen Storage Disease Type Ia
DTX401, an investigational AAV gene therapy for Glycogen Storage Disease Type Ia (GSDIa), represents a significant advancement for Ultragenyx. Phase 3 trial data presented in 2024 demonstrated a substantial decrease in the need for dietary cornstarch, a cornerstone of current GSDIa management. This reduction in cornstarch intake directly translates to improved quality of life for patients suffering from this rare metabolic disorder.
Ultragenyx is actively pursuing regulatory approval, having commenced a rolling Biologics License Application (BLA) submission in mid-2025. The company anticipates a complete BLA submission by the fourth quarter of 2025, setting the stage for a potential market launch in 2026. This timeline positions DTX401 as a key growth driver for Ultragenyx, addressing a critical unmet medical need with no existing curative treatments.
GTX-102 for Angelman Syndrome
GTX-102, a promising therapy for Angelman syndrome, is positioned as a potential Star in Ultragenyx's BCG Matrix. The therapy has achieved a significant milestone with the FDA granting it Breakthrough Therapy Designation, signaling strong potential for accelerated development.
The Phase 3 Aspire study for GTX-102 completed enrollment ahead of schedule in Q2 2025, indicating robust patient interest and a streamlined path to data. Angelman syndrome represents a substantial unmet medical need, and positive Phase 3 results, anticipated in the latter half of 2026, could solidify GTX-102's status as a market leader.
The development and potential commercialization of GTX-102 require considerable investment, reflecting its high growth potential and the significant resources needed to bring such an innovative therapy to market. This strategic focus highlights Ultragenyx's commitment to addressing rare neurological disorders with transformative treatments.
UX143 (Setrusumab) for Osteogenesis Imperfecta
Setrusumab (UX143) is positioned as a significant growth opportunity for Ultragenyx, currently in the Question Mark category of the BCG Matrix. Its Phase 3 Orbit study for osteogenesis imperfecta (OI) is nearing key data readouts, with a second interim analysis anticipated mid-2025 and a potential final analysis in Q4 2025. Success in these trials could unlock a substantial new market for Ultragenyx, given the unmet need in treating this rare brittle bone disease.
- Potential Market: Osteogenesis imperfecta affects approximately 1 in 15,000 births globally, representing a significant patient population with limited therapeutic options.
- Clinical Trial Progress: The Orbit study is a pivotal Phase 3 trial, and its outcomes will be critical in determining UX143's future market potential.
- Growth Trajectory: Positive results could propel UX143 into a Star or Cash Cow status, depending on market penetration and competitive landscape post-launch.
- Financial Impact: Successful commercialization of UX143 would significantly bolster Ultragenyx's revenue streams and market valuation.
Evkeeza's Early Commercialization
Evkeeza, Ultragenyx's therapy for ultra-rare lipid diseases, is currently in its nascent commercial phase outside the United States. Its early performance, with $11 million in Q1 2025 and $15 million in Q2 2025 revenue, indicates a product with significant potential in new territories.
This international expansion, coupled with robust demand, positions Evkeeza as a Question Mark on the BCG matrix. The drug is actively building its market presence and showing promising early traction.
- Evkeeza's early international revenue: $11 million (Q1 2025) and $15 million (Q2 2025).
- Market position: Early commercialization stage outside the US.
- Growth indicator: Demonstrating strong demand building and expanding international presence.
- BCG Matrix classification: Question Mark, with potential to become a Star.
High-Growth, High-Risk: The Question Mark Products
Ultragenyx has several products that fall into the Question Mark category of the BCG Matrix, signifying high growth potential but also high uncertainty. These therapies are in various stages of development and regulatory review, requiring significant investment. Their success hinges on clinical trial outcomes and regulatory approvals, which will determine their future market position.
UX111, a gene therapy for Sanfilippo syndrome type A, faces a crucial PDUFA date of August 18, 2025. DTX401, targeting Glycogen Storage Disease Type Ia, is undergoing a rolling BLA submission with a potential 2026 launch. Setrusumab (UX143) for osteogenesis imperfecta is awaiting key data readouts from its Phase 3 Orbit study in mid-2025 and Q4 2025. Evkeeza, for ultra-rare lipid diseases, is showing promising early international revenue, with $11 million in Q1 2025 and $15 million in Q2 2025.
| Product | Indication | BCG Category | Key Developments (2024-2025) | Potential |
| UX111 | Sanfilippo syndrome type A | Question Mark | PDUFA date August 18, 2025 | First gene therapy for a fatal condition |
| DTX401 | Glycogen Storage Disease Type Ia | Question Mark | Phase 3 data in 2024; Rolling BLA submission mid-2025; Anticipated Q4 2025 complete BLA | Reduce cornstarch dependency; Potential 2026 launch |
| Setrusumab (UX143) | Osteogenesis imperfecta | Question Mark | Phase 3 Orbit study interim analysis mid-2025; Final analysis Q4 2025 | Address unmet need in brittle bone disease |
| Evkeeza | Ultra-rare lipid diseases | Question Mark | Early international commercialization; Q1 2025 revenue: $11M; Q2 2025 revenue: $15M | Expand international presence and revenue |